Form 8-K - Current report:
SEC Accession No. 0001104659-25-052460
Filing Date
2025-05-23
Accepted
2025-05-23 16:31:13
Documents
13
Period of Report
2025-05-20
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2515950d1_8k.htm   iXBRL 8-K 25715
2 EXHIBIT 16.1 tm2515950d1_ex16-1.htm EX-16.1 2755
  Complete submission text file 0001104659-25-052460.txt   196005

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lvtx-20250520.xsd EX-101.SCH 3038
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lvtx-20250520_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lvtx-20250520_pre.xml EX-101.PRE 22374
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2515950d1_8k_htm.xml XML 3665
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40241 | Film No.: 25982911
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)